Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TransCon IL-2 β⁄γ
- Development stage
- Phase 2
- Lead developer
- Ascendis Pharma
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TransCon IL-2 β⁄γ is a novel long-acting prodrug of a modified interleukin-2 (IL‑2) cytokine designed for cancer immunotherapy. It uses hydrogel-based sustained-release technology to deliver an engineered variant of endogenous human interleukin‑2 that selectively binds and activates the intermediate-affinity interleukin‑2 receptor beta/gamma (IL‑2Rβ/γ), while avoiding activation of the high-affinity alpha subunit (IL‑2Rα). This selectivity aims to robustly activate cytotoxic lymphocytes—specifically CD8+ T cells, natural killer (NK) cells, and γδ T cells—while minimizing stimulation of regulatory T cells and eosinophils that are associated with toxicity. The drug is being developed by Ascendis Pharma for the treatment of advanced or metastatic solid tumors as monotherapy or in combination with other agents such as pembrolizumab. Preclinical and early clinical data show durable immune activation with reduced risk of cytokine storm or vascular leak syndrome compared to traditional high-dose aldesleukin therapy[1][6][9].
- Brand names
- TransCon IL-2 β⁄γ
- Other names
- TransCon IL-2 beta/gammaTransCon IL-2β/γ
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on TransCon IL-2 β⁄γ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TransCon IL-2 β⁄γ.